Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.

Autor: Ni J; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Huang M; Peking University Cancer Hospital, Beijing, China., Zhang L; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Wu N; Peking University Cancer Hospital, Beijing, China., Bai CX; Zhongshan Hospital, Fudan University, Shanghai, China., Chen LA; The First Medical Center of Chinese PLA General Hospital, Beijing, China., Liang J; Peking University International Hospital, Beijing, China., Liu Q; Chinese Journal of Lung Cancer, Beijing, China., Wang J; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Zhang FC; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Zhang SY; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Chen C; Fujian Medical University Union Hospital, Fuzhou, China., Chen J; Tianjin Medical University General Hospital, Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin, China., Fang WT; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China., Gao SG; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Hu J; The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China., Jiang T; Tangdu Hospital, Fourth Military Medical University, Xi'an, China., Li SQ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Li HC; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Liao YD; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China., Liu Y; The First Medical Center of Chinese PLA General Hospital, Beijing, China., Liu DR; China-Japan Friendship Hospital, Beijing, China., Liu HX; Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China., Liu JY; Jilin Cancer Hospital, Changchun, China., Liu LX; West China Hospital, Sichuan University, Chengdu, China., Wang MZ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Wang CL; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China., Yang F; Peking University People's Hospital, Beijing, China., Yang Y; Peking University Cancer Hospital, Beijing, China., Zhang LJ; Sun Yat-sen University Cancer Center, Guangzhou, China., Zhi XY; Xuanwu Hospital, Capital Medical University, Beijing, China., Zhong WZ; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China., Guan YZ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Guo XX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., He CX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Li SL; Peking University Cancer Hospital, Beijing, China., Li Y; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Liang NX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Lu FL; Peking University Cancer Hospital, Beijing, China., Lv C; Peking University Cancer Hospital, Beijing, China., Lv W; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Si XY; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Tan FW; National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wang HP; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Wang JS; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Yan S; Peking University Cancer Hospital, Beijing, China., Yang HX; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Zhu HJ; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Zhuang JL; Peking Union Medical Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China., Zhuo ML; Peking University Cancer Hospital, Beijing, China.
Jazyk: angličtina
Zdroj: Thoracic cancer [Thorac Cancer] 2021 May; Vol. 12 (9), pp. 1469-1488. Date of Electronic Publication: 2021 Mar 30.
DOI: 10.1111/1759-7714.13942
Abstrakt: Perioperative adjuvant treatment has become an increasingly important aspect of the management of patients with non-small cell lung cancer (NSCLC). In particular, the success of immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, in patients with lung cancer has increased our expectations for the success of these therapeutics as neoadjuvant immunotherapy. Neoadjuvant therapy is widely used in patients with resectable stage IIIA NSCLC and can reduce primary tumor and lymph node stage, improve the complete resection rate, and eliminate microsatellite foci; however, complete pathological response is rare. Moreover, because the clinical benefit of neoadjuvant therapy is not obvious and may complicate surgery, it has not yet entered the mainstream of clinical treatment. Small-scale clinical studies performed in recent years have shown improvements in the major pathological remission rate after neoadjuvant therapy, suggesting that it will soon become an important part of NSCLC treatment. Nevertheless, neoadjuvant immunotherapy may be accompanied by serious adverse reactions that lead to delay or cancellation of surgery, additional illness, and even death, and have therefore attracted much attention. In this article, we draw on several sources of information, including (i) guidelines on adverse reactions related to immune checkpoint inhibitors, (ii) published data from large-scale clinical studies in thoracic surgery, and (iii) practical experience and published cases, to provide clinical recommendations on adverse events in NSCLC patients induced by perioperative immunotherapy.
(© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: